SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

Autolus Therapeutics plc
Date: May 12, 2025 · CIK: 0001730463 · Accession: 0000000000-25-005022

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-287097

Date
May 12, 2025
Author
Division of
Form
UPLOAD
Company
Autolus Therapeutics plc

Letter

Re: Autolus Therapeutics plc Registration Statement on Form S-1 Filed May 8, 2025 File No. 333-287097 Dear Christian Itin Ph.D.:

May 12, 2025

Christian Itin, Ph.D. Chief Executive Officer Autolus Therapeutics plc The MediaWorks 191 Wood Lane White City London W12 7FP United Kingdom

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Chris Edwards at 202-551-6761 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: William DuVal

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 May 12, 2025

Christian Itin, Ph.D.
Chief Executive Officer
Autolus Therapeutics plc
The MediaWorks
191 Wood Lane
White City
London W12 7FP
United Kingdom

 Re: Autolus Therapeutics plc
 Registration Statement on Form S-1
 Filed May 8, 2025
 File No. 333-287097
Dear Christian Itin Ph.D.:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Chris Edwards at 202-551-6761 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: William DuVal
</TEXT>
</DOCUMENT>